Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real‐life data of prior and concomitant use of psoriasis treatments from the PROSPECT study

Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real‐life... IntroductionPsoriasis is a chronic inflammatory, immune‐mediated skin disease affecting 1–3% of the industrialized population. There are several treatment options available for moderate to severe psoriasis that can provide improvements in clinical assessments of skin symptoms [e.g. Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI)]. The disease is associated with both physical and psychological impairments, and hence, optimal control requires adherence to continuous treatment.PROSPECT (Observational, Descriptive Study of Prior and Concomitant Psoriasis Treatments in Subjects Receiving Secukinumab in the Routine Treatment of Moderate to Severe Plaque‐type Psoriasis; EUPAS10715) is a descriptive study designed to assess prior and concomitant use of psoriasis treatments in subjects receiving secukinumab, and the duration of transition periods from prior treatments to secukinumab treatment in Germany. Previous studies report the prevalence of psoriasis for individuals of all ages in Germany as 2.00% (95% confidence internal (CI): 1.98–2.20) and 2.53% (95% CI: 2.50–2.56). German and European treatment guidelines for psoriasis recommend combinations of various psoriasis treatments for selected subjects and purposes. For example, topical treatments are often combined with both conventional systemic treatments and biologics, and conventional systemic treatments are sometimes combined with biologics. A recent international consensus report http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real‐life data of prior and concomitant use of psoriasis treatments from the PROSPECT study

Loading next page...
1
 
/lp/wiley/secukinumab-treatment-of-moderate-to-severe-plaque-psoriasis-in-ii9eKZcebJ

References (19)

Publisher
Wiley
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
DOI
10.1111/jdv.14604
pmid
28960469
Publisher site
See Article on Publisher Site

Abstract

IntroductionPsoriasis is a chronic inflammatory, immune‐mediated skin disease affecting 1–3% of the industrialized population. There are several treatment options available for moderate to severe psoriasis that can provide improvements in clinical assessments of skin symptoms [e.g. Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI)]. The disease is associated with both physical and psychological impairments, and hence, optimal control requires adherence to continuous treatment.PROSPECT (Observational, Descriptive Study of Prior and Concomitant Psoriasis Treatments in Subjects Receiving Secukinumab in the Routine Treatment of Moderate to Severe Plaque‐type Psoriasis; EUPAS10715) is a descriptive study designed to assess prior and concomitant use of psoriasis treatments in subjects receiving secukinumab, and the duration of transition periods from prior treatments to secukinumab treatment in Germany. Previous studies report the prevalence of psoriasis for individuals of all ages in Germany as 2.00% (95% confidence internal (CI): 1.98–2.20) and 2.53% (95% CI: 2.50–2.56). German and European treatment guidelines for psoriasis recommend combinations of various psoriasis treatments for selected subjects and purposes. For example, topical treatments are often combined with both conventional systemic treatments and biologics, and conventional systemic treatments are sometimes combined with biologics. A recent international consensus report

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

There are no references for this article.